Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer
Hannelore Denys(Ghent University Hospital), Mona M. Van Steenberghe(Roche (Belgium)), Georgeta Fried(Roche (Switzerland)), Noa Ben-Baruch(Kaplan Medical Center), Marc Martens(AZ Turnhout), Marie-Pascale Graas(Centre Hospitalier Chrétien), Corina L. Martinez-Mena(Centre Hospitalier Universitaire de Saint-Pierre), Ella Evron(Sidney Kimmel Comprehensive Cancer Center), Randal D’hondt, Christof Vulsteke(University of Antwerp)
Cited by 44
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|645
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
|Gynecologic Oncology|2015|301
DNA methylation of <i>RASSF1A, HIN‐1, RAR‐β, Cyclin D2</i> and <i>Twist</i> in <i>in situ</i> and invasive lobular breast carcinoma
|International Journal of Cancer|2003|251